Tirzepatide Approved for CV Risk Reduction in High-Risk Patients with Diabetes

In August 2026, the U.S. FDA approved tirzepatide (Mounjaro) to reduce the risk of major adverse cardiovascular events among adults with type 2 diabetes who are at high risk for such events. Tirzepatide activates both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide receptors. It is now the fourth GLP-1 agonist with a cardiovascular risk-reduction indication, joining dulaglutide, semaglutide, and liraglutide.